

The listing of claims presented below replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A pharmaceutical composition for treating a subject with recurrent spontaneous abortion ~~characterized by~~ comprising a therapeutically effective amount of chromosome No. 2 or fragment thereof containing fibronectin encoding gene ~~derived~~ obtained from a male ~~the spouse~~ mate of said subject.
2. (Currently Amended) The pharmaceutical composition according to claim 1, ~~characterized by~~ comprising isolated and intact chromosome No.2.
3. (Currently Amended) The pharmaceutical composition according to claim 2, ~~characterized in that~~ wherein said chromosome No.2 is isolated from somatocytes in M phase.
4. (Currently Amended) A pharmaceutical composition for treating a subject with recurrent spontaneous abortion ~~characterized by~~ comprising a therapeutically effective amount of a mixture of chromosome No. 2 or fragment thereof containing fibronectin encoding gene ~~derived~~ obtained from a plurality of males.
5. (Currently Amended) The pharmaceutical composition according to claim 4 ~~characterized by~~ comprising isolated and intact chromosome No.2.
6. (Currently Amended) The pharmaceutical composition according to claim 5 ~~characterized in that~~ wherein said chromosome No.2 is isolated from somatocytes in M phase.

7. (Currently Amended) The pharmaceutical composition according to claim 4 ~~characterized in that~~ wherein the number of said plurality of males is more than 3.

8. (Currently Amended) The pharmaceutical composition according to claim 4 ~~characterized in that~~ wherein the number of said plurality of males is more than 10.

9. (Currently Amended) The pharmaceutical composition according to claim 4 ~~characterized in that~~ wherein the number of said plurality of males is more than 20.

10. (Currently Amended) Chromosome No. 2 or fragment thereof containing fibronectin encoding gene ~~derived~~ obtained from a male as a medicament.

11. (Cancel)

12. (Cancel)

14. (Currently amended) A method for treating a subject with recurrent spontaneous abortion comprising administering to the subject in need of treatment a therapeutically effective amount of ~~The method according to claim 13, wherein said substance capable of lowering the in-vivo level of antinuclear antibody is~~ chromosome No. 2 or fragment thereof containing fibronectin encoding gene ~~derived~~ obtained from a male ~~the spouse~~ mate of said subject.

15. (Currently amended) The method according to claim 14, wherein ~~characterized in that~~ isolated and intact chromosome No.2 is administered.

16. (Currently amended) The method according to claim 15, wherein ~~characterized in that~~ said chromosome No.2 is isolated from somatocytes in M phase.

17. (Currently amended) A method for treating a subject with recurrent spontaneous abortion comprising administering to the subject in need of treatment a

therapeutically effective amount of ~~The method according to claim 13, wherein said~~
~~substance capable of lowering the in vivo level of antinuclear antibody is a mixture of~~
chromosome No. 2 or fragments thereof containing fibronectin encoding
gene, ~~derived~~ obtained from a plurality of males.

18. (Currently amended) The method according to claim 17, wherein ~~characterized in that~~ a
mixture of isolated and intact chromosome No.2 is administered.

19. (Currently amended) The method according to claim 18, wherein ~~characterized in that~~
said chromosome No.2 is isolated from somatocytes in M phase.

20. (Currently amended) The method according to claim 17, wherein ~~characterized in that~~ the
number of said plurality of males is more than 3.

21. (Currently amended) The method according to claim 20, wherein ~~characterized in that~~ the
number of said plurality of males is more than 10.

22. (Currently amended) The method according to claim 21, wherein ~~characterized in that~~ the
number of said plurality of males is more than 20.